Management of Thalassemia in Pregnancy

Preconception Assessment and Counseling

The American Heart Association recommends that pregnant women with thalassemia major should be managed at expert centers with multidisciplinary teams, requiring preconception cardiac assessment with T2* MRI, maintenance of hemoglobin ≈10 g/dL through intensified transfusions, thromboprophylaxis, and consideration of deferoxamine chelation restart in late second trimester if severe iron overload exists 1, 2
Cardiac evaluation is mandatory before conception, assessing cardiac T2* and left ventricular function/dimensions using cardiac MRI to identify iron-related cardiac damage 1, 2
Women with severe cardiac or hepatic iron overload, or those with preexisting cardiac disease, face substantially higher maternal risk and require specialized planning 1, 2

Blood consumption increases during pregnancy to ensure optimal fetal growth, and hemoglobin should be maintained at approximately 10 g/dL throughout pregnancy 1, 2

The American College of Cardiology recommends stopping teratogenic chelators at conception, discontinuing deferiprone and deferasirox due to teratogenic concerns 1, 2
In patients with severe cardiac or hepatic iron overload, deferoxamine can be restarted toward the end of the second trimester, balancing maternal cardiac risk against potential fetal effects 1, 2

Close cardiac surveillance is critical, monitoring cardiac function carefully throughout pregnancy as increased blood volume and blood pressure changes may compromise heart function 1, 2
Cardiac complications occur in 1.1% to 15.6% of pregnancies in women with thalassemia 1, 2
Patients with cardiac T2* <6 ms have approximately 14% risk of arrhythmia within one year, predominantly atrial fibrillation 1, 5

Prophylaxis with heparin or low-molecular-weight heparin is indicated, particularly in splenectomized patients and those with thalassemia intermedia 1, 2
Splenectomized patients have significantly elevated thrombotic risk requiring careful monitoring 1, 2, 3

Spontaneous miscarriage and fetal loss occur in 9% to 33.3% of pregnancies 1, 2, 4
Gestational diabetes, preeclampsia, and hypertension are reported frequently 1, 2, 4
Preterm births occur at increased rates due to maternal or obstetric complications 1, 2, 4

Cesarean rates range from 24% to 100% due to fetopelvic disproportion, osteoporosis, maternal HIV infection, or patient preference 1, 2, 4
Plan delivery at centers with expertise in high-risk obstetrics and thalassemia management 1, 2, 4

Avoid therapeutic iron supplementation, starting only low-dose prophylactic iron (30 mg/day) at first prenatal visit, not therapeutic doses 6
The most common error is treating thalassemia minor with therapeutic iron doses (60-120 mg/day), which provides no benefit and may cause iron overload 6

Failing to perform preconception cardiac assessment with T2* MRI in thalassemia major patients 1, 2
Inadequate transfusion support allowing hemoglobin to fall below 10 g/dL 1, 2
Omitting thromboprophylaxis in splenectomized patients 1, 2, 3
Treating thalassemia minor with therapeutic iron doses instead of low-dose prophylaxis 6
Managing high-risk thalassemia pregnancies outside expert centers with multidisciplinary teams 1, 2, 4
Failing to screen partner for carrier status, missing at-risk pregnancies 4